Wockhardt’s yet another novel antibiotic Miqnaf™ (Nafithromycin) receives favourable recommendation from Subject Expert Committee of Central Drugs Standard Control Organization (CDSCO) for the Treatment for Community – Acquired Bacterial Pneumonia (CABP)